Raymond James Increases Liquidia (NASDAQ:LQDA) Price Target to $29.00

Liquidia (NASDAQ:LQDA) had its price target raised by Raymond James from $27.00 to $29.00 in a report released on Friday,Benzinga reports. Raymond James currently has a strong-buy rating on the stock.

Other research analysts also recently issued research reports about the stock. Needham & Company LLC restated a “buy” rating and set a $25.00 price target on shares of Liquidia in a research report on Thursday, April 10th. Scotiabank reissued an “outperform” rating on shares of Liquidia in a report on Monday, May 5th. Finally, HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research report on Thursday, March 20th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Liquidia presently has a consensus rating of “Buy” and an average price target of $27.13.

Liquidia Price Performance

Shares of LQDA stock opened at $15.32 on Friday. Liquidia has a 1-year low of $8.26 and a 1-year high of $16.81. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -9.40 and a beta of 0.24. The stock has a 50 day simple moving average of $14.25 and a 200-day simple moving average of $13.18.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.03). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. Analysts anticipate that Liquidia will post -1.51 earnings per share for the current fiscal year.

Insider Activity at Liquidia

In other Liquidia news, CEO Roger Jeffs sold 14,130 shares of Liquidia stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $191,744.10. Following the completion of the transaction, the chief executive officer now directly owns 1,006,420 shares of the company’s stock, valued at $13,657,119.40. The trade was a 1.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jason Adair sold 1,856 shares of the stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $25,185.92. Following the completion of the sale, the insider now owns 184,304 shares in the company, valued at approximately $2,501,005.28. The trade was a 1.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 33,138 shares of company stock valued at $450,233. Corporate insiders own 26.50% of the company’s stock.

Hedge Funds Weigh In On Liquidia

A number of institutional investors and hedge funds have recently modified their holdings of LQDA. Hurley Capital LLC acquired a new stake in shares of Liquidia during the first quarter worth about $32,000. GAMMA Investing LLC lifted its holdings in Liquidia by 65.6% in the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company’s stock valued at $44,000 after acquiring an additional 1,173 shares during the period. Steward Partners Investment Advisory LLC purchased a new stake in Liquidia during the fourth quarter worth about $59,000. Summit Investment Advisors Inc. grew its holdings in shares of Liquidia by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock worth $78,000 after acquiring an additional 1,719 shares during the period. Finally, D. E. Shaw & Co. Inc. acquired a new position in shares of Liquidia during the 4th quarter worth $142,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).